Vitamin D is a fat-soluble vitamin that your body can make after sun exposure and that also comes from foods and supplements. Human studies show its clearest role is in bone health and in raising vitamin D status in certain groups; findings for many other outcomes are mixed, limited, or uncertain.
The main blood measure is 25-hydroxyvitamin D, often written as 25(OH)D. The NIH Office of Dietary Supplements fact sheet says this is the main indicator of vitamin D status, although laboratory methods vary and one “optimal” level for every person has not been established.
Quick facts: forms, study doses, and uses
| Question | What the research page shows |
|---|---|
| Common forms | Vitamin D2 (ergocalciferol) and D3 (cholecalciferol). Both raise 25(OH)D; D3 generally raises it more and keeps it higher for longer. |
| Doses used in studies | At least 200 IU daily in preterm-infant trials; 35 mcg weekly in one low-birth-weight infant trial; 800 IU or more daily in higher-dose preterm comparisons; 4,000 IU daily and 60,000 IU monthly in a high-risk-pregnancy review. |
| Typical study length | Until discharge or term-corrected age in preterm-infant studies; six months in one low-birth-weight infant study. Other studies varied. |
| Main studied uses here | Vitamin D status and bone-related outcomes, pregnancy outcomes, mortality in older adults, and associations with kidney or gastric cancer outcomes. |
What do human studies show?
Vitamin D status in preterm and low-birth-weight infants
A 2026 Cochrane review combined 34 randomized or quasi-randomized trials with 5,012 infants. In four studies with 385 preterm infants, vitamin D versus no supplement probably reduced vitamin D deficiency through discharge or term-corrected age: risk ratio 0.20. In one trial of 453 term low-birth-weight infants, 35 mcg of vitamin D3 weekly from age seven days to six months also probably reduced deficiency at six months.
More was not simply better. In 11 preterm-infant studies, 800 IU or more daily reduced deficiency compared with 200 to under 800 IU daily, but it also probably increased vitamin D excess. The review found little or no difference in some bone measures and remained uncertain about several other outcomes. These are infant studies, so they do not answer what the same doses mean for adults.
Bone health
The NIH fact sheet says the Food and Nutrition Board found evidence sufficient for vitamin D’s role in bone health and normal calcium metabolism. It also says the evidence was inadequate or too contradictory to reach firm conclusions for many other health outcomes. That distinction matters: a change in a blood number is not automatically a patient benefit. Surrogate outcomes in trials explains why those are different questions.
Preeclampsia in high-risk pregnancy
A 2026 systematic review and network meta-analysis of randomized trials reported that 4,000 IU daily and 60,000 IU monthly were associated with lower estimated preeclampsia risk than placebo in high-risk pregnancies. The reported risk ratios were 0.21 and 0.36, respectively. But the review describes the direct evidence as limited, mixed across studies, and partly indirect, with low certainty. It treats the results as hypothesis-generating rather than a basis for clinical practice.
Mortality in adults age 75 and older
A 2026 review reanalyzed 25 randomized trials and focused on eight lower-risk-of-bias trials with 30,320 participants. It found a small mortality signal in favor of vitamin D: risk ratio 0.96, with a confidence interval from 0.92 to 1.00. The authors say no included trial was conclusive, so this possible small effect still needs confirmation.
Kidney disease progression
A 2026 systematic review of 11 observational studies found that lower 25(OH)D levels were associated with higher odds of chronic kidney disease progression. The overall association had very low certainty and substantial variation between studies. Because these were observational studies, they cannot show that supplementation prevents kidney-function decline.
Gastric cancer
A 2026 systematic review of 24 observational studies found no significant pooled association between dietary vitamin D and gastric cancer risk. Four studies of blood 25(OH)D showed a non-significant tendency toward lower levels in people with gastric cancer. The findings vary by the type of exposure studied and do not show that vitamin D changes cancer risk.
What doses did researchers use?
These are study doses, not personal dosing instructions. The infant trials used daily cumulative doses of at least 200 IU; higher-dose comparisons used 800 IU or more daily. One term low-birth-weight infant study used 35 mcg of D3 weekly for six months. The high-risk-pregnancy network review examined 4,000 IU daily and 60,000 IU monthly among other regimens.
Vitamin D can appear in micrograms (mcg) or International Units (IU). The NIH fact sheet states that 1 mcg equals 40 IU. Study design changes how much a result can tell you; the vitamin D research landscape explains the difference between study types and dose comparisons.
Safety, side effects, and medicine interactions
The NIH fact sheet notes that blood 25(OH)D levels above 125 nmol/L (50 ng/mL) are linked to potential adverse effects, particularly above 150 nmol/L (60 ng/mL). In the preterm-infant review, higher-dose vitamin D probably increased vitamin D excess compared with lower-dose regimens.
Vitamin D is processed through the liver and kidneys before it becomes active. If you use prescription medicines or have a health condition that affects calcium, kidney function, or vitamin D handling, bring the exact label and your medication list to a clinician or pharmacist before adding or changing a supplement. Do not start, stop, or change a prescribed medicine based on an ingredient page.
Who should talk to a clinician first?
Talk to a clinician first if you are pregnant, caring for an infant born preterm or at low birth weight, have kidney disease, have had abnormal vitamin D or calcium results, or use prescription medicines. These groups appear in the research because their needs, monitoring, and risks can differ from those of generally healthy adults.
What is still unknown?
Vitamin D research has many open questions. The NIH fact sheet says an optimal 25(OH)D level for bone and general health has not been established for every person. It also says the evidence for many outcomes beyond bone health is inadequate or contradictory. The pregnancy review needs larger direct trials, and the older-adult mortality review found no conclusive trial.
Results can also conflict because studies use different populations, forms, doses, durations, laboratory tests, and outcomes. A study that raises 25(OH)D answers a different question from a study that measures fractures, symptoms, or survival.
How to read a vitamin D label
Start with the amount per serving and whether it is stated in mcg, IU, or both. Check whether the label names D2 or D3. A proprietary blend can make it harder to see the amount of each ingredient, so look for a label that gives a specific vitamin D amount rather than only a blend total.
Keep the serving size in view, especially if a label uses more than one capsule, drop, or gummy per serving. If you are comparing nutrients, see how the evidence is separated by ingredient in zinc evidence and safety and vitamin E evidence and safety.
By ClinicalStudyConnect.com Research Desk
This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.